Current Edition

breast cancer

Novartis’ breast cancer drug Kisqali succeeds in phase 3 study in premenopausal women

Novartis’ Kisqali (ribociclib) combination therapy has succeeded in a phase 3 study in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) …

Continue Reading →